Press Releases

WASHINGTON, DC, October 27, 2016 — Faith United Against Alzheimer’s – an UsAgainstAlzheimer’s Coalition mobilizing the faith community in the fight against Alzheimer’s disease – today announced that The Balm In Gilead has joined the Coalition, bringing decades of experience working with African American churches in the United States to tackle urgent health challenges.

WASHINGTON, DC, October 13, 2016 — Faith United Against Alzheimer’s – an UsAgainstAlzheimer’s Coalition mobilizing the faith community in the fight against Alzheimer’s disease – today announced that Volunteers of America has joined the Coalition, a positive step in acknowledging and confronting the devastation Alzheimer’s is wreaking in communities across the nation.

WASHINGTON, DC, September 23, 2016—The following is a statement by Faith United Against Alzheimer’s on Pope Francis’ remarks in honor of World Alzheimer’s Day on Wednesday, September 21.

Pope Francis said, “Today is the 23rd World Day for Alzheimer’s, which carries the theme ‘Remember me.’ I invite all those present to ‘remember,’ with the care of Mary and the tenderness of the Merciful Jesus, all those who are afflicted by this disease and their loved ones, so that they may know our closeness. We also pray for people who find themselves near the sick, even those with less obvious cases, that they may be seen with eyes full of love.” 

 

New Report Underscores Urgent Need for Investments in Alzheimer’s Research, Health Literacy and Clinical Trials for U.S. Latinos

LOS ANGELES, September 21, 2016—Unless a medical breakthrough is discovered that prevents, cures or slows the progression of Alzheimer’s disease, the incidence and cost of Alzheimer’s on U.S. Latinos will grow exponentially by 2060, according to a report released today by the USC Edward R. Roybal Institute on Aging at the USC Suzanne Dworak-Peck School of Social Work and LatinosAgainstAlzheimer’s, a network of UsAgainstAlzheimer’s.

WASHINGTON, DC, August 4, 2016—The Centers for Medicare & Medicaid Services (CMS) decision not to reimburse everyday Americans for using what the FDA determined to be an effective diagnostic tool was found to be “arbitrary and capricious” by a Federal court. The reason? Because Medicare is reimbursing for a less effective diagnostic tool and did not explain why it would not do so for a more innovative tool.

Pages

^ Back to Top